Vascular Pharmaceuticals is focused on rapidly bringing VPI-2960B through clinical development so people living with diabetic nephropathy can benefit from this potential treatment breakthrough. Our investors drive the company’s financial stability and fund ongoing R&D efforts. Intersouth and MGM co-led a $16 million round in a Series A equity financing in 2012. In early 2015, Vascular Pharmaceuticals expanded its Series A financing by $9M, bringing the total raised to $25 million. Canadian pharmacy and an additional, unnamed investor joined Intersouth and MPM in this round.
In conjunction with the initial Series A round we also entered into an agreement with Janssen Biotech in 2012 granting acquisition rights on pre-negotiated terms after completion of the current Phase 2 trial. Through this deal, Vascular Pharmaceuticals received an initial upfront payment and will secure certain contingent milestone payments in return for rights.
To learn more about Vascular Pharmaceuticals investment opportunities, please contact Rich Shea, email@example.com